Evidence map›Paper›PMID 23914148›Full record

ArticleJournal of oncology practice2013

2013 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy.

Michael N Neuss, Martha Polovich, Kristen McNiff, Peg Esper, Terry R Gilmore, Kristine B LeFebvre, Lisa Schulmeister, Joseph O Jacobson

Erratum issuedAbstract read
In one paragraph

Article in Journal of oncology practice, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 45 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Recommendations by the Spanish Society of Hospital Pharmacy, the Spanish Society of Oncology Nursing and the Spanish Society of Medical Oncology for the safe management of antineoplastic medication in cancer patients.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Guideline
  5. Pooled it
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Assessment of patients' understanding of and adherence to oral anticancer medication (OAM): Results of a cross-sectional institutional pilot study.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2021
    Article
  17. Enhancing patients' understanding of and adherence to oral anticancer medication: Results of a longitudinal pilot intervention.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2021
    Article
  18. From theory to practice: implementing a standardized, interactive education session on oral anticancer medication (OAM) for patients and their caregivers.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Article
  19. Article
  20. New Oral Anti-Cancer Drugs and Medication Safety.Deutsches Arzteblatt international · 2019
    Review
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

8 authors.

Michael N NeussVanderbilt Ingram Cancer Center, Nashville TN; Duke Oncology Network, Durham, NC; University of Michigan Comprehensive Cancer Center, Ann Arbor MI; American Society of Clinical Oncology, Alexandria, VA; Oncology Nursing Society, Pittsburgh, PA; Oncology Nursing Consultant, New Orleans, LA; and Dana Farber Cancer Institute, Boston, MA.
Martha Polovich
Kristen McNiff
Peg Esper
Terry R Gilmore
Kristine B LeFebvre
Lisa Schulmeister
Joseph O Jacobson

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2009, ASCO and the Oncology Nursing Society (ONS) published standards for the safe use of parenteral chemotherapy in the outpatient setting, including issues of practitioner orders, preparation, and administration of medication. In 2011, these were updated to include inpatient facilities. In December 2011, a multistakeholder workgroup met to address the issues associated with orally administered antineoplastics, under the leadership of ASCO and ONS. The workgroup participants developed recommended standards, which were presented for public comment. Public comments informed final edits, and the final standards were reviewed and approved by the ASCO and ONS Boards of Directors. Significant newly identified recommendations include those associated with drug prescription and the necessity of ascertaining that prescriptions are filled. In addition, the importance of patient and family education regarding administration schedules, exception procedures, disposal of unused oral medication, and aspects of continuity of care across settings were identified. This article presents the newly developed standards.

Indexed as

Administration, OralAntineoplastic AgentsBiomarkers, PharmacologicalHumansNeoplasmsOncology NursingPatient SafetyPractice Guidelines as TopicSocieties, NursingUnited StatesAntineoplastic AgentsBiomarkers, Pharmacological

Identifiers

PMID23914148
PMCPMC3731124

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.